reports
- Aurelien Sivignon
- Yan Derocles
- Jean Danjou
- Aurelien Sivignon
- Yan Derocles
- Jean Danjou
- Christophe-Raphaël Ganet
- Christophe-Raphaël Ganet
- Jacob Mekhael
- Thibault Leneeuw
- Jacob Mekhael
MaaT Pharma Final Xervyteg phase 3 data confirm strong survival outcom...
MaaT reported the final results from the phase 3 (ARES) trial of Xervyteg (MaaT013, microbiome therapy, enema formulation) in aGvHD at the American Society of Hematology (ASH) conference, being held 6-9 December 2025. The final OS results from the phase 3 (ARES) trial of MaaT013 coming in at 54% at 1 year confirm the previously reported 54% probability of survival that was shared with the topline readout in January 2025. We believe this brings a significant benefit vs. the 15% 1-year OS reported...
- Ahmed Ben Salem
- Baptiste Salaville
- Oddo Sustainability Team
- Baptiste Salaville
- Bojan Djurickovic
- Oddo Sustainability Team
- Christophe-Raphaël Ganet
- Christophe-Raphaël Ganet
- Guy Sips
- Jacob Mekhael
- Livio Luyten
- Wim Hoste
- Jacob Mekhael
MaaT Pharma Model update post € 9.1m capital raise
MaaT announced the completion of a capital raise of € 9.1m (at a 9% discount to closing price prior to deal announcement), and expects to use the net proceeds of € 8.7m to fund Xervyteg commercialisation preparation in Europe, advance MaaT033 development, and prepare for a pivotal US study of Xervyteg in 2026. This capital raise unlocks a € 6m EIB tranche, extending the company's cash runway to August 2026. Upon anticipated EU approval of Xervyteg in mid-2026, MaaT is eligible to receive a € 12m...
- Mathijs Geerts Danau
MaaT Pharma Launches capital increase for gross proceeds of € 9m ...
MaaT announced the launch of a capital increase through a private placement with qualified investors and retail investors. The company intends to raise € 9m, the funds will extend the runway to summer 2026 (previously February 2026). MaaT plans to use the proceeds to fund the company's development and commercialization of Xervyteg. Trading will be suspended until at least November 14 after market close. We view this raise as a positive and reiterate our BUY rating and € 17 TP.
- Hilde Van Boxstael
- Lynn Hautekeete
- Mathijs Geerts Danau
- Wim Lewi
- Jacob Mekhael
MaaT Pharma Uneventful 3Q25 cash and revenues
MaaT reported uneventful 3Q25 cash and revenues, where its cash and cash equivalents came in at € 22.4m, providing the company with a cash runway until the end of February 2026. We note that continued growth in revenues from MaaT013's early access program (only billable in France) is a positive sign ahead of its potential EMA approval expected mid-2026. MaaT did not provide a pipeline update, though it has previously guided for results from the investigator initiated phase 2a (PICASSO) trial of ...
- Jacob Mekhael
ASH abstracts: Autolus, Galapagos, MaaT
The abstracts for presentations at the American Society of Haematology conference (ASH, 6-9 December) became available yesterday during the day (HERE). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (new data for Aucatzyl in paediatric ALL, real world data in adult ALL, amongst others), Galapagos (additional CAR-T data in r/r MCL and r/r DLBCL) and MaaT (longer follow up from ...
- Luis de Toledo Heras
TEMN TEMENOS AG
SOP SOPRA STERIA GROUP SA
OUT1V OUTOKUMPU OYJ
SBMO SBM OFFSHORE NV
KORI KORIAN SA
TYRES NOKIAN RENKAAT OYJ
ASY ASSYSTEM SA
VETO VETOQUINOL SA
PIG HAULOTTE GROUP SA
CDA COMPAGNIE DES ALPES SA
NOEJ NORMA GROUP SE
BB SOCIETE BIC SA
BAMNB KONINKLIJKE BAM GROEP NV
VID VIDRALA SA
MMT METROPOLE TELEVISION SA
AED AEDIFICA SA
SHOT SCANDIC HOTELS GROUP
WAF SILTRONIC AG
MELE MELEXIS NV
ENC ENCE ENERGIA Y CELULOSA SA
SMHN SUESS MICROTEC AG
ALR ALIOR BANK SA
CSM CORBION NV
SAE SHOP APOTHEKE EUROPE NV
ALD ALD SA
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
ALLFG ALLFUNDS (UK) LTD
ORP ORPEA
SHA SCHAEFFLER AG
- Luis de Toledo Heras
TEMN TEMENOS AG
SOP SOPRA STERIA GROUP SA
OUT1V OUTOKUMPU OYJ
SBMO SBM OFFSHORE NV
KORI KORIAN SA
TYRES NOKIAN RENKAAT OYJ
ASY ASSYSTEM SA
VETO VETOQUINOL SA
PIG HAULOTTE GROUP SA
CDA COMPAGNIE DES ALPES SA
NOEJ NORMA GROUP SE
BB SOCIETE BIC SA
BAMNB KONINKLIJKE BAM GROEP NV
VID VIDRALA SA
MMT METROPOLE TELEVISION SA
AED AEDIFICA SA
SHOT SCANDIC HOTELS GROUP
WAF SILTRONIC AG
MELE MELEXIS NV
ENC ENCE ENERGIA Y CELULOSA SA
SMHN SUESS MICROTEC AG
ALR ALIOR BANK SA
CSM CORBION NV
SAE SHOP APOTHEKE EUROPE NV
ALD ALD SA
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
ALLFG ALLFUNDS (UK) LTD
ORP ORPEA
SHA SCHAEFFLER AG
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.